Amgen's Imdelltra Shows Significant Efficacy in Advanced Lung Cancer Treatment
Amgen (AMGN) has reported positive clinical results for its cancer drug, Imdelltra, when used in combination with AstraZeneca's Imfinzi. The combination therapy demonstrated a 58% reduction in the risk of death for patients with extensive-stage small cell lung cancer, extending median survival to 21.1 months compared to 12.7 months with Imfinzi alone. This development follows a strong year for Amgen, which has seen its stock value rise by over 40% in 2026. The company's financial performance is bolstered by significant growth across its portfolio, including 22 products that achieved double-digit sales growth in the second quarter. Imdelltra itself generated $288 million in revenue during the first half of 2026, representing 115% growth.